High Dose Indium-111 Pentetreotide Therapy in Somatostatin Receptor Expressing Neuroendocrine Neoplasms.
Unknown Phase 2,Phase 3 NCT00442533
Study Description
The purpose of this study is to determine if High-dose 111In-Pentetreotide known as NeuroendoMedix®, is an effective treatment for Neuroendocrine Tumors.
Study Details
- Registry ID:
- NCT00442533
- Conditions:
- Neuroendocrine Tumors
- Phase:
- Phase 2,Phase 3
- Target Enrollment:
- 200 participants
- Start Date:
- Healthy Volunteers:
- No
Study Locations (2 sites)
-
Excel Diagnostic Imaging Clinics
Houston, Texas, United States -
St. Lukes Episcopal Hospital
Houston, Texas, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.org.